9/ #ASH24 Abstract 256 (Cheruvalath) Preemptive strategy #2 to make BCMA bsAbs safer in #MMsm Don't wait until IgG < 400 (this is myeloma, not rheumatology)... give IVIG now! Or even start IVIG right before bsAb starts... both better than waiting! ash.confex.com/ash/2024/webpr…

Vaccines are good. Anti-depressants are good. Modern medicine is good. Fluoride in water is safe and protects teeth.

#ASH24 #mmsm A side note: Heloise Cheruvalath is a medical student #ASHkudos managed smart questions by Luciano J Costa with the support of Meera Mohan who is a great mentor

CONGRESS | #ASH24 | Heloise Cheruvalath Heloise Cheruvalath Medical College of Wisconsin shares data on the effects of IVIG on infections in patients treated with teclistamab. The use of IVIG was associated with a reduction in infections and an increase in OS. The use of tocilizumab for CRS was

#ASH24 Excellent work by Heloise Cheruvalath Meera Mohan et al showing value of IVIG with BCMA-targeted bsAbs in #MMsm. 🤯 OS benefit?? Likely other confounders, e.g. evolving ⬆️ IVIG use vs ⬇️ pandemic lethality... ... But clearly the days of waiting for IVIG ≤400 are gone!